The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation

Summary

Impaired endothelial recovery after the implantation of drug-eluting stents is a major concern because of the increased risk for late stent thrombosis. The disruption of the chemokine axis CXCL12/CXCR4 inhibits neointima formation by blocking the recruitment of smooth muscle progenitor cells. To directly compare a CXCR4-targeting treatment strategy with drugs that are currently used for stent coating, we studied the effects of the CXCR4 antagonist POL5551 and the drug sirolimus on neointima formation. Apolipoprotein E-deficient mice were treated with POL5551 or sirolimus continuously for 28 days after a carotid wire injury. POL5551 inhibited neointima formation by 63% (for a dosage of 2 mg/kg/day) and by 70% (for a dosage of 20 mg/kg/day). In comparison, sirolimus reduced the neointimal area by 69%. In contrast to treatment with POL5551 during the first three days after injury, injection of POL5551 (20 mg/kg) once per day for 28 days diminished neointimal hyperplasia by 53%. An analysis of the cellular composition of the neointima showed a reduction in the relative smooth muscle cell (SMC) and macrophage content in mice that had been treated with a high dose of POL5551. In contrast, the diminished SMC content after sirolimus treatment was associated with a neointimal enrichment of macrophages. Furthermore, endothelial recovery was impaired by sirolimus, but not by POL5551. Therefore, the inhibition of CXCR4 by POL5551 is equally effective in preventing neointima formation as sirolimus, but POL5551 might be more beneficial because treatment with it results in a more stable lesion phenotype and because it does not impair re-endothelialisation.

Keywords

Restenosis - stents - vascular remodelling - chemokines

• References

• 1 Weintraub WS.. The pathophysiology and burden of restenosis. Am J Cardiol 2007; 100: 3K-9K.
• 2 Garg S, Serruys PW. Coronary Stents. Current Status. J Am Coll Cardiol 2010; 56: S1-S42.
• 3 Stone GW, Moses JW, Ellis SG. et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.. N Engl J Med 2007; 356: 998-1008.
• 4 Finn AV, Joner M, Nakazawa G. et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.. Circulation 2007; 115: 2435-2441.
• 5 Joner M, Finn AV, Farb A. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.. J Am Coll Cardiol 2006; 48: 193-202.
• 6 Smith Jr. SC, Feldman TE, Hirshfeld Jr. JW. et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.
• 7 Farb A, Boam AB.. Stent thrombosis redux--the FDA perspective. N Engl J Med 2007; 356: 984-987.
• 8 Sata M, Saiura A, Kunisato A. et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis.. Nat Med 2002; 8: 403-409.
• 9 Schober A, Knarren S, Lietz M. et al. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice.. Circulation 2003; 108: 2491-2497.
• 10 Zernecke A, Schober A, Bot I. et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells.. Circ Res 2005; 96: 784-791.
• 11 Schober A.. Chemokines in vascular dysfunction and remodeling.. Arterioscler Thromb Vasc Biol 2008; 28: 1950-1959.
• 12 Subramanian P, Karshovska E, Reinhard P. et al. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation.. Circ Res 2010; 107: 96-105.
• 13 Yokoi H, Yamada H, Tsubakimoto Y. et al. Bone marrow AT1 augments neointima formation by promoting mobilization of smooth muscle progenitors via platelet-derived SDF-1.. Arterioscler Thromb Vasc Biol 2009; 30: 60-67.
• 14 Massberg S, Konrad I, Schurzinger K. et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo.. J Exp Med 2006; 203: 1221-1233.
• 15 Karshovska E, Zagorac D, Zernecke A. et al. A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury.. J Thromb Haemost 2008; 6: 1812-1815.
• 16 Zernecke A, Bot I, Djalali-Talab Y. et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008; 102: 209-217.
• 17 Robinson J, Demarco S, Gombert F. et al. The design, structures and therapeutic potential of protein epitope mimetics.. Drug Discov Today 2008; 13: 944-951.
• 18 Hausleiter J, Kastrati A, Mehilli J. et al. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with instent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.. Circulation 2004; 110: 790-795.
• 19 Sakihama H, Masunaga T, Yamashita K. et al. Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis.. Circulation 2004; 110: 2924-2930.
• 20 Schober A, Hristov M, Kofler S. et al. CD34+CD140b+ cells and circulating CXCL12 correlate with the angiographically assessed severity of cardiac allograft vasculopathy.. Eur Heart J 2011; 32: 476-484.
• 21 Mehta NN, Li M, William D. et al. The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels.. Eur Heart J 2011; 32: 963-971.
• 22 Haribabu B, Richardson RM, Fisher I. et al. Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem 1997; 272: 28726-28731.
• 23 Karshovska E, Zernecke A, Sevilmis G. et al. Expression of HIF-1alpha in injured arteries controls SDF-1alpha mediated neointima formation in apolipoprotein E deficient mice.. Arterioscler Thromb Vasc Biol 2007; 27: 2540-2547.
• 24 Nemenoff RA, Simpson PA, Furgeson SB. et al. Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha.. Circ Res 2008; 102: 1036-1045.
• 25 Fukuda D, Sata M, Tanaka K. et al. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells.. Circulation 2005; 111: 926-931.
• 26 Inoue T, Sata M, Hikichi Y. et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: impact on restenosis.. Circulation 2007; 115: 553-561.
• 27 Linton MF, Atkinson JB, Fazio S.. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 1995; 267: 1034-1037.
• 28 Yu H, Stoneman V, Clarke M. et al. Bone marrow-derived smooth muscle-like cells are infrequent in advanced primary atherosclerotic plaques but promote atherosclerosis.. Arterioscler Thromb Vasc Biol 2011; 31: 1291-1299.
• 29 Nakazawa G, Vorpahl M, Finn AV. et al. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis.. JACC Cardiovasc Imaging 2009; 2: 625-628.
• 30 Higo T, Ueda Y, Oyabu J. et al. Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study.. JACC Cardiovasc Imaging 2009; 2: 616-624.
• 31 Liehn EA, Schober A, Weber C.. Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 1891-1896.
• 32 Hristov M, Zernecke A, Bidzhekov K. et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury.. Circ Res 2007; 100: 590-597.
• 33 Volin MV, Joseph L, Shockley MS. et al. Chemokine receptor CXCR4 expression in endothelium. Biochem Biophys Res Commun 1998; 242: 46-53.